12-Month Data Expected Later This Year
Theravance Clipped by Mixed Relovair Data in 6-Month Trials
By Jennifer Boggs
Friday, June 3, 2011
Despite hailing two six-month pivotal studies' successes for Relovair in chronic obstructive pulmonary disease (COPD), South San Francisco-based Theravance Inc. saw its shares dinged by nearly a dollar Thursday as investors focused on the one endpoint that fell short of statistical significance.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.